June 24, 2013
by Endia Vereen
The US Supreme Court ruled 5-4 Monday in Mutual Pharmaceutical Company, Inc. v. Bartlett that generic drug design defect claims that turn on the adequacy of a drug's warnings are preempted by federal law under PLIVA, Inc. v. Mensing. Justice Samuel Alito delivered the opinion of the court, which ...[read more]
June 23, 2011
by Julia Zebley
The US Supreme Court on Thursday voted 5-4 to reverse the lower court in PLIVA, Inc. v. Mensing, holding that since generic drugs and their warnings are managed by the Food and Drug Administration (FDA), their federal regulations on warning labels preempt state law on warning labels. Justice ...[read more]
December 11, 2010
by Brian Jackson
The US Supreme Court on Friday granted certiorari in three cases related to the duty of generic drug manufacturers to list possible side effects on the labels of medicines they produce. The three cases, PLIVA Inc. v. Mensing, Actavis v. Mensing and Actavis v. Demahy were consolidated and will ...[read more]

Support JURIST

We rely on our readers to keep JURIST running

 Donate now!

© Copyright JURIST Legal News and Research Services, Inc., 2013.